Rest of 2025 Rich With Catalysts for Immunotherapy Co.
Source: Jason Kolbert  (4/9/25)
These anticipated events will advance the oncology firm's lead candidate, for lung-only metastatic osteosarcoma, toward commercialization, noted a D. Boral Capital report. More >

Four-Year Data on New Drug for Early AD Positive
Source: Dr. Ram Selvaraju  (4/9/25)
Long-term treatment with this small molecule seems feasible given its safety and tolerability profile, noted an H.C. Wainwright & Co. report. More >

Share Price Appreciation of Biotech Due Over Next Six Months
Source: Dr. David Nierengarten  (4/8/25)
Given its robust pipeline, numerous milestones for this Outperform-rated company are slated to occur in the near-term, noted a Wedbush report. More >

New Therapy for AATD Could be Best in Class
Source: Patrick Trucchio  (4/8/25)
Updated trial data show it to be safe and efficacious and have a dual mechanism of action, noted an H.C. Wainwright & Co. report. More >

Biotech Firm Uncovers Gene Therapy Breakthrough in Portugal
Source: Streetwise Reports  (4/8/25)
Beam Therapeutics Inc. (BEAM:NASDAQ) shows strong momentum with positive analyst ratings and new data from its BEAM-302 trial in AATD. Find out why experts see major upside potential. More >

Biotech Co. Has Promising AI-Accelerated Pipeline
Source: Alexander Rihane  (4/7/25)
Rakovina Therapeutics Inc. (RKV:TSX.V) recently gained analyst coverage from First Berlin Equity Research. Read on to see why this company rates the stock a Buy. More >

Immunotherapy Company Finds Rare Cancer Breakthrough in U.S.
Source: Streetwise Reports  (4/7/25)
OS Therapies Inc. (OSTX:NYSEAMERICAN) announced that its lead drug OST-HER2 was granted Orphan Drug Designation by the FDA for osteosarcoma. Read how the designation could accelerate development and create new investor interest. More >

Biotech Company Finds High-Impact Alzheimer's Therapy in Europe
Source: Streetwise Reports  (4/7/25)
Anavex Life Sciences Corp. (AVXL:NASDAQ) earned positive analyst coverage following new long-term data for blarcamesine in early Alzheimer's disease. Experts pointed to safety, durability, and potential approval pathways. Read more about what they said. More >

Biopharma Firm Discovers High-Impact CNS Therapy in U.S. With Breakthrough Results
Source: Streetwise Reports  (4/4/25)
Reviva Pharmaceuticals Holdings Inc. (RVPH: NASDAQ) is gaining attention with strong Phase 3 results for its lead CNS candidate, brilaroxazine. Here's what analysts are seeing in its long-term potential. More >

Regenerative Medicine Firm OK'd To Advance Trial in T1D
Source: Streetwise Reports  (4/3/25)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) says the Data Safety Monitoring Board supports the ongoing evaluation of the biotech's Cell Pouch Bio-hybrid Organ in this indication. More >

Cell Pouch Co. Peer Aborts Program Using Like Device
Source: Dr. Douglas Loe  (4/3/25)
The implications for Cell Pouch, an implantable cell delivery vehicle, and the biotech behind it are positive, noted a Leede Financial Inc. report. More >

Ascending Dose Trial of FABP5 Inhibitor to Read Out Soon
Source: Jason Kolbert  (4/3/25)
Meanwhile, a representative from the company advancing the small molecule in the clinic is slated to speak about it at a conference this week, noted a D. Boral Capital report. More >

New Jersey Pharma Co. Shares Positive Pediatric Study
Source: Dr. Ram Selvaraju  (4/2/25)
Aquestive Therapeutics Inc. (AQST:NASDAQ) recently reported that it completed New Drug Application (NDA) submission for Anaphylm and positive pediatric study data for the non-device-based epinephrine product candidate, noted an H.C. Wainwright & Co. research note. More >

Clean Tech Co. Achieves Record-Breaking Revenue for Exceptional Growth
Source: Streetwise Reports  (4/1/25)
BioLargo Inc. (BLGO:OTCQX) announced in its annual report that in 2024 it saw record revenues and an increase of 45% over the year before. Read why an expert and an analyst both like this clean technology company's story. More >

GMP Production of Exosomes Slated for Later This Year
Source: Jason Kolbert  (3/31/25)
This is a next big step for the biotech in moving its investigational exosome therapy for chronic inflammation into the clinic, noted a D. Boral Capital report. More >

Biotech Co. Advances AI-Generated Cancer Treatments
Source: Streetwise Reports  (3/28/25)
Rakovina Therapeutics Inc. (RKV:TSX.V) receives the first synthesized batch of artificial intelligence-generated ATR inhibitor compounds developed in collaboration with Variational AI. Find out why the technology could revolutionize the way we treat cancer. More >

Biotech Advances Revolutionary Treatment for Neurodegenerative Diseases
Source: Streetwise Reports  (3/28/25)
Clinical-stage biotechnology company Coya Therapeutics Inc.'s (COYA:NASDAQ) regulatory T cell-derived exosome (Treg exosome) program is set to enter Good Manufacturing Production (GMP) late this year, paving the way for an initial clinical study. Find out why one analyst calls the company's work a "potential breakthrough." More >

Chen Highlights His Premium Silver, Gold Opportunities for Q2
Source: Streetwise Reports  (3/25/25)
Even with tariff chaos, asset manager Chen Lin of What is Chen Buying? What is Chen Selling? said he is still bullish in the near term for gold silver. Find out which stocks are his top picks for the coming quarter. More >

PDUFA Date Nearing for New PSVT Drug
Source: Patrick Trucchio  (3/19/25)
If approved, commercialization will start mid-year; the biopharma behind the treatment offers a potential return of 1,052%, noted an H.C. Wainwright & Co. report. More >

Two Use Cases for AI in Healthcare
Source: Streetwise Reports  (3/14/25)
In both, proprietary software platforms analyze heaps of data, but one focuses on genetics, the other neurology. Learn more about the companies behind the technology. More >

US$200M Deal Accelerates Phase 3 Gene Therapy for Parkinsons
Source: Streetwise Reports  (3/14/25)
MeiraGTx Holdings Plc.'s (MGTX:NASDAQ) partnership with Hologen AI secures US$200 million to advance its Phase 3 gene therapy for Parkinson's. With regulatory milestones ahead, here's what's next.

More >

Biotech Stock Looks Like Is Has a Great Set Up
Source: Clive Maund  (3/12/25)
Technical Analyst Clive Maund explains why he thinks Hemostemix Inc. (HEM:TSXV; HMTXF:OTCQB; 2VF0:FSE) is an Immediate Strong Buy. More >

Utah Biotech's Treatment Demonstrates Significant Survival Advantage for ALS Patients
Source: Jason Kolbert  (3/12/25)
Utah biotech Clene Inc. (CLNN:NASDAQ) recently shared new data, reporting the survival benefit of its CNM-Au8 treatment for ALS patients, according to a D. Boral Capital research note. More >

AI Study Tracks Unexpected Cognitive Gains in Vascular Dementia Trial
Source: Streetwise Reports  (3/11/25)
Hemostemix Inc.'s (HEM:TSXV; HMTXF:OTCQB; 2VF0:FSE) Phase 1 trial, in collaboration with Firefly Neuroscience Inc. (AIFF:NASDAQ), is evaluating ACP-01s impact on vascular dementia using AI-driven brain analysis. Early insights could reshape treatment approaches. More >

Biotech Advancing Pivotal Phase III Breast Cancer Trial
Source: Dr. Douglas Loe  (3/11/25)
Oncolytics Biotech Inc. (ONCY:NASDAQ; ONC:TSX) recently updated its timelines for the company's clinical testing, regulatory review, and potential commercial launch of its oncolytic reovirus formulation pelareorep in breast cancer, according to a report from Leede Financial Inc. More >